| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514630000 | A ring or polycyclo ring system in a substituent E is attached indirectly to the carboxamide nitrogen or to an amino nitrogen in substituent E by acyclic nonionic bonding | 38 |
| 20080280991 | SUBSTITUTED NAPHTHALENES - Disclosed herein are substituted naphthalene-based melatonin (MT) receptor modulators and/or 5-HT receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 11-13-2008 |
| 20090069434 | Cystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it - Crystalline form VI of the compound of formula (I): | 03-12-2009 |
| 20090143475 | BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS - Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided. | 06-04-2009 |
| 20090298948 | COLCHICINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 12-03-2009 |
| 20100004340 | NAPHTHYL(ETHYL) ACETAMIDES - This disclosure relates to novel melatonin analogues or naphthyl(ethyl)acetamides, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual melatoninergic agonist and serotoninergic antagonist. | 01-07-2010 |
| 20100063158 | Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it - Crystalline form III of the compound of formula (I): | 03-11-2010 |
| 20100137446 | NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 06-03-2010 |
| 20100204336 | Formoterol Tartrate Process and Polymorph - A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph. | 08-12-2010 |
| 20100267836 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES - Novel melatonin ligands of Formula I: | 10-21-2010 |
| 20110039940 | Methods for Concomitant Administration of Colchicine and a Second Active Agent - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 02-17-2011 |
| 20110098359 | Compositions and Methods for Treatment of Glaucoma - A new use for paracetamol in a method of treating glaucoma, which method comprises administering to a patient in need of such treatment 500 mg to 1000 mg of paracetamol in oral format 4 to 6 hourly. An ophthalmic solution is also provided containing between 0.1 to 5% of paracetamol which is administered as one to two drops in each eye 4 to 6 hourly. The ophthalmic solution further includes one or more of the following excipients: hydroxypropylmethylcellulose, benzalconium chloride, polyacrylic acid such as Teargel®. | 04-28-2011 |
| 20110301243 | NOVEL METHOD - The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent. | 12-08-2011 |
| 20120004313 | CRYSTALLINE FORM VI OF AGOMELATINE, PREPARATION METHOD AND APPLICATION THEREOF - The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2θ 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°. Said new crystalline form is characterized by high purity, stability and good reproducibility, and thus is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms. | 01-05-2012 |
| 20120035267 | PARACETAMOL FOR PARENTERAL ADMINSTRATION - The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 μS cm | 02-09-2012 |
| 20120208891 | METHODS FOR CONCOMITANT ADMINISTRATION OF COLCHICINE AND A SECOND ACTIVE AGENT - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 08-16-2012 |
| 20120252901 | AGOMELATINE AND PHARMACEUTICAL COMPOSITIONS THEREOF - Agomelatine crystal, which is a drug for treating depression, and pharmaceutical compositions thereof are provided. The X-ray powder diffraction spectra of such agomelatine crystal, which is irradiated by Cu-Kα and showed by 2θ(degree), has characteristic diffraction peaks at 12.84, 13.84, 16.14, 18.56, 19.12, 20.86, 21.20, 23.84; its IR absorption pattern has characteristic absorption peaks at about 3234, 3060, 2940, 1638, 1511, 1436, 1249, 1215, 1184, 1032, 908, 828, 755, 588 cm-1, and its DSC endothermic transition temperature is 97.6° C. The use of the agomelatine crystal as an active ingredient in preparing a medicament for the treatment of depression is also provided. | 10-04-2012 |
| 20120309837 | Bronchodilating Beta-Agonist Compositions and Methods - Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided. | 12-06-2012 |
| 20120309838 | USE OF AGOMELATINE IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD) - The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Obsessive-Compulsive Disorder (OCD). | 12-06-2012 |
| 20120316245 | CO-CRYSTALS OF AGOMELATINE, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - New co-crystal of agomelatine composed of:
| 12-13-2012 |
| 20130005820 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF - The present invention relates to an agomelatine hydrochloride hydrate of formula I, preparation and use thereof, and to pharmaceutical composition containing it. The agomelatine hydrohalide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps. | 01-03-2013 |
| 20130041040 | SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATINE - The invention relates to a solid buccal pharmaceutical composition comprising agomelatine intended for systemic action. | 02-14-2013 |
| 20130131181 | USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS - The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas. | 05-23-2013 |
| 20130217776 | Combination of a Serotonin Reuptake Inhibitor and Agomelatine - The present invention relates to the use of a combination of agomelatine and a serotonin reuptake inhibitor (SRIs), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders. | 08-22-2013 |
| 20130217777 | PROCESS FOR MAKING MULTIPARTICULATE GASTRORETENTIVE DOSAGE FORMS - The instant invention relates to a process for making inherent low density particles, comprising the steps of (i) providing a powder mixture comprising a swelling agent; (ii) granulating the powder of step (i) with a granulating solution comprising a lipophilic agent into granules and (iii) drying the granules of step (ii). The instant invention further relates to multiparticulate oral gastro-retentive dosage forms comprising the inherent low density particles obtainable by the process. | 08-22-2013 |
| 20130261189 | POLYVINYLPYRROLIDONE-CONTAINING ACETAMINOPHEN LIQUID FORMULATIONS - A pharmaceutical formulation contains 10-60% by weight acetaminophen as the only active ingredient and a solvent system for dissolving the acetaminophen. The formulation is free of any ionizing agent and its solvent system includes water, polyethylene glycol, and polyvinylpyrrolidone that is 2-50% by weight and has a molecular weight of 2,000 to 1,500,000. Also disclosed is another acetaminophen formulation containing polyvinylpyrrolidone as high as 25-50% by weight. | 10-03-2013 |
| 20130289125 | Methods and Compositions for Pest Control - Methods and compositions for pest control, and more particularly for control of ants, e.g., of the subfamily Myrmicinae, using tyramides. | 10-31-2013 |
| 20130317112 | STORAGE-STABLE FORMULATION OF PARACETAMOL IN AQUEOUS SOLUTION - The present invention relates to a method for the production of a formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent, comprising the steps of (i) dissolving paracetamol in an aqueous solvent comprising an isotonic agent that is sodium chloride and a buffer agent that is sodium citrate, having a temperature between 65° C. and 95° C. and having pH between 5.0 and 6.0 in a reaction vessel, (ii) replacing the remaining air in the vessel by an inert gas, such as nitrogen, and cooling the solution so formed to a temperature below 38° C., (iii) adding cysteine hydrochloride to the solution without mechanical agitation, and (iv) closing the reaction vessel and mechanically agitating the solution in a nitrogen atmosphere. The further relates to a formulation prepared according to the method. | 11-28-2013 |
| 20140011883 | CRYSTAL FORM VII OF AGOMELATINE, PREPARATION METHOD AND USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention provides a new crystalline form VII of agomelatine, its method of preparation, application and pharmaceutical composition. This new crystalline form offers high purity, a stable crystalline structure and good reproducibility, while its method of production lends itself well to large scale production. In terms of stability and purity, it is superior to the numerous crystalline forms which have hitherto been reported. As a result, the crystalline form VII of the present invention possesses advantages in pharmaceutical preparation. | 01-09-2014 |
| 20140045946 | Compositions and Methods for Treatment of Glaucoma - A new use for paracetamol in a method of treating glaucoma, which method comprises administering to a patient in need of such treatment 500 mg to 1000 mg of paracetamol in oral format 4 to 6 hourly. An ophthalmic solution is also provided containing between 0.1 to 5% of paracetamol which is administered as one to two drops in each eye 4 to 6 hourly. The ophthalmic solution further includes one or more of the following excipients: hydroxypropylmethylcellulose, benzalconium chloride, polyacrylic acid such as Teargel®. | 02-13-2014 |
| 20140088197 | MIXED CRYSTAL AGOMELATINE (FORM VIII), PREPARATION METHOD AND USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention provides a mixed crystalline form VIII of agomelatine, its method of preparation, application and pharmaceutical composition. The said mixed crystal consists mainly of crystalline form VI of agomelatine. The said mixed crystalline form is stable and has good reproducibility. Through stability tests, it has been found to be superior to the crystalline form VI in terms of stability. As a result, the crystalline form VIII of the present invention possesses advantages in pharmaceutical preparation. | 03-27-2014 |
| 20140235726 | METHOD OF IMPROVING COGNITION AND INCREASING DENDRITIC COMPLEXITY IN HUMANS WITH DOWN SYNDROME AND COMPOSITIONS THEREFOR - A method of improving cognition in a patient with Down syndrome, which entails administering one or more β2 adrenergic receptor agonists to the patient in an amount and with a frequency effective to improve cognition of the patient as measured by contextual learning tests | 08-21-2014 |
| 20150045442 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES - Novel melatonin ligands of Formula I: | 02-12-2015 |
| 20150105471 | PARACETAMOL FOR PARENTERAL ADMINISTRATION - The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 μS cm | 04-16-2015 |
| 20150141519 | AGOMELATINE SULFURIC ACID COMPLEX, AND PREPARATION METHOD AND APPLICATION THEREOF - The present invention relates to an Agomelatine sulfuric acid complex in formula (I) and the preparation method thereof (HX=H | 05-21-2015 |
| 20150359743 | SPRAY DRIED COMPOSITIONS HAVING DIFFERENT DISSOLUTION PROFILES AND PROCESSES FOR THEIR PREPARATION - The present disclosure provides compositions having different dissolution profiles. In particular, the compositions are formulated by adjusting the types and/or amounts of excipients and/or surfactants, and the compositions are prepared by spray drying processes. | 12-17-2015 |
| 20160113875 | ALKYL CELLULOSE FOR USE IN TABLETING AND SOLID PREPARATION COMPRISING SAME - Provided is an alkyl cellulose excellent in formability when added even in a small amount and not causing marked delay in disintegration; a solid preparation including it; and a method for producing the solid preparation. More specifically, provided is an alkyl cellulose for use in tableting, the alkyl cellulose having a specific surface area of from 0.5 to 10.0 m | 04-28-2016 |
| 20160120825 | STABLE CRYSTAL X-FORM AGOMELATINE TABLET AND PREPARATION METHOD THEREOF - Disclosed are a stable crystal X-form agomelatine tablet and a preparation method thereof. The method comprises the following steps: selecting one or more protective agents, adding the protective agents into pure water, stirring, heating the mixture to 35-40° C., dissolving them until the solution is clear, cooling the solution to room temperature, adding crystal X-form agomelatine, stirring the mixture until homogeneous, and obtaining the protective agents containing the crystal X-form agomelatine for use; and then, after mixing a part of the pharmaceutical excipient until homogeneous, again adding the protective agents containing the crystal X-form agomelatine, mixing and pelletizing them according to a wet method and drying to obtain particles containing the crystal X-form agomelatine; and finally, adding the other pharmaceutical excipients into the particles according to a proportion, mixing them until homogeneous and tabletting them. | 05-05-2016 |
| 20160193162 | STABLE CRYSTAL I-FORM AGOMELATINE TABLET AND PREPARATION METHOD THEREOF | 07-07-2016 |
